ArticleReviews in urology2007
Anticholinergics and central nervous system effects: are we confused?
Article in Reviews in urology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis.British journal of clinical pharmacology · 2015Pooled it
- [Study of anticholinergic burden in chronic treatments of outpatients in the Community Pharmacy].Farmaceuticos comunitarios · 2025Observational
- Mirabegron in the Management of Overactive Bladder Syndrome.International journal of women's health · 2022Review
- Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.Current medical research and opinion · 2021Article
- Anticholinergic Drug Induced Cognitive and Physical Impairment: Results from the InCHIANTI Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020Article
- Are Anticholinergic Medications Associated With Increased Risk of Dementia and Behavioral and Psychological Symptoms of Dementia? A Nationwide 15-Year Follow-Up Cohort Study in Taiwan.Frontiers in pharmacology · 2020Article
- Differential Prescribing of Antimuscarinic Agents in Older Adults with Cognitive Impairment.Drugs & aging · 2018Article
- Potentially Harmful Medication Use and Decline in Health-Related Quality of Life among Community-Dwelling Older Adults.Drugs - real world outcomes · 2017Article
- Making a Bad Diagnosis Worse? Suspect Drug Management of Urinary Incontinence in Persons with Dementia.Journal of the American Geriatrics Society · 2017Article
- Rational prescribing: the principles of drug selection.Clinical medicine (London, England) · 2016Article
- Anticholinergics for overactive bladder therapy: central nervous system effects.CNS neuroscience & therapeutics · 2012Review
- Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.Drug safety · 2011Review
- To clamp or not to clamp? Bladder management by suprapubic catheterization in patients with neurogenic bladder dysfunction.World journal of urology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The central nervous system (CNS) effects of anticholinergic agents have been documented in various patient populations and to varying degrees in case reports, brain-activity surrogates, and computerized cognitive testing. The older patient population with overactive bladder represents a group at increased risk of cognitive impairment and other CNS side effects associated with antimuscarinic agents. The complexity of the effect of anticholinergic agents on CNS function requires an increased level of careful investigation. Studies need to be performed in the at-risk population with multiple, validated tests at clinically prescribed doses in acute and chronic situations. These studies need to take into account the effect of commonly prescribed dosing regimens, with doses selected to represent with equivalent bladder potency. The alterations in the serum levels and parent/metabolite effects contributed by metabolic issues or drug delivery systems require special attention.
Indexed as
Identifiers
18231615PMC2213887W108407354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.